BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Domínguez-Ríos R, Sánchez-Ramírez DR, Ruiz-Saray K, Oceguera-Basurto PE, Almada M, Juárez J, Zepeda-Moreno A, Del Toro-Arreola A, Topete A, Daneri-Navarro A. Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. Colloids Surf B Biointerfaces 2019;178:199-207. [PMID: 30856589 DOI: 10.1016/j.colsurfb.2019.03.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang Z, Guo B, Yue S, Zhao S, Meng F, Zhong Z. HER-2-mediated nano-delivery of molecular targeted drug potently suppresses orthotopic epithelial ovarian cancer and metastasis. Int J Pharm 2022;625:122126. [PMID: 35995316 DOI: 10.1016/j.ijpharm.2022.122126] [Reference Citation Analysis]
2 Bai B, Weng S, Wu Z, Xie Z, Tang J, Yang Q. Fabrication of Dual-Responsive pH and Reduction of Dual Anticancer Drugs Conjugates Dextran Self-Assembly for Osteosarcoma Cancer Treatment. Process Biochemistry 2022. [DOI: 10.1016/j.procbio.2022.08.005] [Reference Citation Analysis]
3 Dodda JM, Remiš T, Rotimi S, Yeh YC. Progress in the drug encapsulation of poly(lactic-co-glycolic acid) and folate-decorated poly(ethylene glycol)-poly(lactic-co-glycolic acid) conjugates for selective cancer treatment. J Mater Chem B 2022;10:4127-41. [PMID: 35593381 DOI: 10.1039/d2tb00469k] [Reference Citation Analysis]
4 Wu SY, Wu FG, Chen X. Antibody-Incorporated Nanomedicines for Cancer Therapy. Adv Mater 2022;:e2109210. [PMID: 35142395 DOI: 10.1002/adma.202109210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Deng H, Liu W, Yang X, Li K, Liao W, Zhao P, Yang Y, Wei H, Wang J, Chen Y. Preliminary evaluation and in vitro cytotoxicity studies of [131I]I-trastuzumab in HER2 expressing ovarian cancer cells. J Radioanal Nucl Chem. [DOI: 10.1007/s10967-022-08329-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 El-hammadi MM, Arias JL. Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines. Nanomaterials 2022;12:354. [DOI: 10.3390/nano12030354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Ghandehari S, Homayouni Tabrizi M, Izadi Nia J, Goodarzi MT. Anti-inflammatory and Antioxidant Properties of PLGA Nanoparticles Produced From Kombucha Extract on A2780 Human Ovarian Cancer Cell Line. Avicenna J Med Biochem 2021;9:65-71. [DOI: 10.34172/ajmb.2021.12] [Reference Citation Analysis]
8 Rasouli M, Fallah N, Bekeschus S. Combining Nanotechnology and Gas Plasma as an Emerging Platform for Cancer Therapy: Mechanism and Therapeutic Implication. Oxid Med Cell Longev 2021;2021:2990326. [PMID: 34745414 DOI: 10.1155/2021/2990326] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
9 Fonseca M, Macedo AS, Lima SAC, Reis S, Soares R, Fonte P. Evaluation of the Antitumour and Antiproliferative Effect of Xanthohumol-Loaded PLGA Nanoparticles on Melanoma. Materials (Basel) 2021;14:6421. [PMID: 34771946 DOI: 10.3390/ma14216421] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Maliyakkal N, Appadath Beeran A, Udupa N. Nanoparticles of cisplatin augment drug accumulations and inhibit multidrug resistance transporters in human glioblastoma cells. Saudi Pharm J 2021;29:857-73. [PMID: 34408546 DOI: 10.1016/j.jsps.2021.07.001] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Fernández-Álvarez F, García-García G, Arias JL. A Tri-Stimuli Responsive (Maghemite/PLGA)/Chitosan Nanostructure with Promising Applications in Lung Cancer. Pharmaceutics 2021;13:1232. [PMID: 34452193 DOI: 10.3390/pharmaceutics13081232] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Zhou N, Wang W, Li H, Jiang D, Zhong X. Development and investigation of dual potent anticancer drug-loaded nanoparticles for the treatment of lung cancer therapy. Process Biochemistry 2021;106:42-9. [DOI: 10.1016/j.procbio.2021.03.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
13 Alkahtani S, Alarifi S, Albasher G, Al-Zharani M, Aljarba NH, Almarzoug MH, Alhoshani NM, Al-Johani NS, Alothaid H, Alkahtane AA. Poly Lactic-Co-Glycolic Acid- (PLGA-) Loaded Nanoformulation of Cisplatin as a Therapeutic Approach for Breast Cancers. Oxid Med Cell Longev 2021;2021:5834418. [PMID: 34257812 DOI: 10.1155/2021/5834418] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Boztepe T, Castro GR, León IE. Lipid, polymeric, inorganic-based drug delivery applications for platinum-based anticancer drugs. Int J Pharm 2021;605:120788. [PMID: 34116182 DOI: 10.1016/j.ijpharm.2021.120788] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
15 Gupta PK, Gahtori R, Govarthanan K, Sharma V, Pappuru S, Pandit S, Mathuriya AS, Dholpuria S, Bishi DK. Recent trends in biodegradable polyester nanomaterials for cancer therapy. Mater Sci Eng C Mater Biol Appl 2021;127:112198. [PMID: 34225851 DOI: 10.1016/j.msec.2021.112198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zajda J, Wróblewska A, Ruzik L, Matczuk M. Methodology for characterization of platinum-based drug's targeted delivery nanosystems. J Control Release 2021;335:178-90. [PMID: 34022322 DOI: 10.1016/j.jconrel.2021.05.022] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
17 Sargazi S, Hajinezhad MR, Barani M, Mukhtar M, Rahdar A, Baino F, Karimi P, Pandey S. F127/Cisplatin Microemulsions: In Vitro, In Vivo and Computational Studies. Applied Sciences 2021;11:3006. [DOI: 10.3390/app11073006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
18 Tchounwou PB, Dasari S, Noubissi FK, Ray P, Kumar S. Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy. J Exp Pharmacol 2021;13:303-28. [PMID: 33776489 DOI: 10.2147/JEP.S267383] [Cited by in Crossref: 5] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]
19 Chiu HI, Samad NA, Fang L, Lim V. Cytotoxicity of targeted PLGA nanoparticles: a systematic review. RSC Adv 2021;11:9433-49. [PMID: 35423427 DOI: 10.1039/d1ra00074h] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
20 Gagliardi A, Giuliano E, Venkateswararao E, Fresta M, Bulotta S, Awasthi V, Cosco D. Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors. Front Pharmacol 2021;12:601626. [PMID: 33613290 DOI: 10.3389/fphar.2021.601626] [Cited by in Crossref: 17] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
21 Zafar A, Alruwaili NK, Imam SS, Alharbi KS, Afzal M, Alotaibi NH, Yasir M, Elmowafy M, Alshehri S. Novel nanotechnology approaches for diagnosis and therapy of breast, ovarian and cervical cancer in female: A review. Journal of Drug Delivery Science and Technology 2021;61:102198. [DOI: 10.1016/j.jddst.2020.102198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Fernández-Álvarez F, Caro C, García-García G, García-Martín ML, Arias JL. Engineering of stealth (maghemite/PLGA)/chitosan (core/shell)/shell nanocomposites with potential applications for combined MRI and hyperthermia against cancer. J Mater Chem B 2021;9:4963-80. [PMID: 34114575 DOI: 10.1039/d1tb00354b] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Fang W, Jin R, Mu W. Near-infrared mediated polymer-coated carbon nanodots loaded cisplatin for targeted care management of lung cancer therapy. Process Biochemistry 2020;99:27-35. [DOI: 10.1016/j.procbio.2020.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
24 Li Y, Gao Y, Zhang X, Guo H, Gao H. Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy. International Journal of Pharmaceutics 2020;591:119986. [DOI: 10.1016/j.ijpharm.2020.119986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
25 Ahmad J, Ameeduzzafar, Ahmad MZ, Akhter H. Surface-Engineered Cancer Nanomedicine: Rational Design and Recent Progress. Curr Pharm Des 2020;26:1181-90. [PMID: 32056517 DOI: 10.2174/1381612826666200214110645] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
26 Kostrhunova H, Zajac J, Markova L, Brabec V, Kasparkova J. A Multi-action PtIV Conjugate with Oleate and Cinnamate Ligands Targets Human Epithelial Growth Factor Receptor HER2 in Aggressive Breast Cancer Cells. Angew Chem Int Ed Engl 2020;59:21157-62. [PMID: 32750194 DOI: 10.1002/anie.202009491] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
27 Kostrhunova H, Zajac J, Markova L, Brabec V, Kasparkova J. A Multi‐action Pt IV Conjugate with Oleate and Cinnamate Ligands Targets Human Epithelial Growth Factor Receptor HER2 in Aggressive Breast Cancer Cells. Angew Chem 2020;132:21343-8. [DOI: 10.1002/ange.202009491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Nieto C, Vega MA, Martín Del Valle EM. Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine. Nanomaterials (Basel) 2020;10:E1674. [PMID: 32859026 DOI: 10.3390/nano10091674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
29 Yuan Y, Li E, Zhao J, Wu B, Na Z, Cheng W, Jing H. Highly penetrating nanobubble polymer enhances LINC00511-siRNA delivery for improving the chemosensitivity of triple-negative breast cancer. Anticancer Drugs 2021;32:178-88. [PMID: 32826414 DOI: 10.1097/CAD.0000000000000985] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
30 Gong H, Nie D, Li Z. Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy. Curr Cancer Drug Targets 2020;20:853-67. [PMID: 32807056 DOI: 10.2174/1568009620999200816130218] [Reference Citation Analysis]
31 Dana P, Bunthot S, Suktham K, Surassmo S, Yata T, Namdee K, Yingmema W, Yimsoo T, Ruktanonchai UR, Sathornsumetee S, Saengkrit N. Active targeting liposome-PLGA composite for cisplatin delivery against cervical cancer. Colloids Surf B Biointerfaces 2020;196:111270. [PMID: 32777659 DOI: 10.1016/j.colsurfb.2020.111270] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
32 Xu Y, Wang L, Pan D, Yan J, Wang X, Yang R, Li M, Liu Y, Yang M. Synthesis of a novel 89Zr-labeled HER2 affibody and its application study in tumor PET imaging. EJNMMI Res 2020;10:58. [PMID: 32495181 DOI: 10.1186/s13550-020-00649-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
33 Jia YY, Zhang JJ, Zhang YX, Wang W, Li C, Zhou SY, Zhang BL. Construction of redox-responsive tumor targeted cisplatin nano-delivery system for effective cancer chemotherapy. Int J Pharm 2020;580:119190. [PMID: 32151664 DOI: 10.1016/j.ijpharm.2020.119190] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
34 Marques AC, Costa PJ, Velho S, Amaral MH. Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies. J Control Release 2020;320:180-200. [PMID: 31978444 DOI: 10.1016/j.jconrel.2020.01.035] [Cited by in Crossref: 47] [Cited by in F6Publishing: 74] [Article Influence: 23.5] [Reference Citation Analysis]
35 Oliveira CG, Dalmolin LF, Silva RTC, Lopez RFV, Maia PIS, Moreto JA. PLGA-nanoparticles loaded with a thiosemicarbazone derived palladium( ii ) complex as a potential agent to new formulations for human ovarian carcinoma treatment. New J Chem 2020;44:14928-35. [DOI: 10.1039/d0nj00580k] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Pornpitchanarong C, Rojanarata T, Opanasopit P, Ngawhirunpat T, Patrojanasophon P. Synthesis of novel N-vinylpyrrolidone/acrylic acid nanoparticles as drug delivery carriers of cisplatin to cancer cells. Colloids Surf B Biointerfaces 2020;185:110566. [PMID: 31655265 DOI: 10.1016/j.colsurfb.2019.110566] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
37 Fernandes E, Ferreira D, Peixoto A, Freitas R, Relvas-Santos M, Palmeira C, Martins G, Barros A, Santos LL, Sarmento B, Ferreira JA. Glycoengineered nanoparticles enhance the delivery of 5-fluoroucil and paclitaxel to gastric cancer cells of high metastatic potential. Int J Pharm 2019;570:118646. [PMID: 31465836 DOI: 10.1016/j.ijpharm.2019.118646] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
38 Miodragović Ð, Swindell EP, Waxali ZS, Bogachkov A, O'Halloran TV. Beyond Cisplatin: Combination Therapy with Arsenic Trioxide. Inorganica Chim Acta 2019;496:119030. [PMID: 32863421 DOI: 10.1016/j.ica.2019.119030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]